Sodium-Glucose Cotransporter-2 Inhibitors have been used in the treatment of Diabetes Type 2 since 2013.
Mode Of Action
SGLT2 inhibitors lower the threshold in the kidneys for excreting glucose, thus lowering the blood sugar level, while the urine sugar level will go up.
- Genital and urinary tract infections
- Diabetic ketoacidosis
- In combination with other diabetic drugs, it may increase the risk of hypoglycaemia.
- Kidney injury
- Low blood pressure
- Increase in cholesterol
+ see FDA Warnings below
- Kidney disease (nephropathy)
- Those with a high amputation risk
Brands, generic name in brackets:
- Foxiga ( Dapagliflozin)
- Invokana (Canagliflozin)
- Jardiance (Empagliflozin)
- Increased risk of a serious infections of the genital area (2018)
- Increased risk of leg and foot amputations (2017)
- Acidosis and serious urinary tract infections (2015)
- Increased risk for bone fracture (2015)
www.fda.gov, Blood Sugar 101 by Jenny Ruhl, www.diabetes.co.uk
This article is reproduced with permission from dLife.in Original Source: https://www.dlife.in/news-and-research-articles-on-diabetes-obesity-lipids/diabetes-oral-drugs-sglt2-inhibitors/